CDKN2A and pancreatic adenocarcinoma: Moreover, some targeted therapies, including the KRAS, CDKN2A, TP53, SMAD4, and other NRG1 or NTRK gene, also show poor outcomes in patients having advanced PAAD (Wood & Hruban, 2012; Maitra & Hruban, 2008).